Last reviewed · How we verify
NCT06911931
Visual Perception in Schizophrenia
NA trial testing EEG measure of visual processing in Schizophrenia Disorders in 84 participants. Currently enrolling.
31 January 2027
Quick facts
| Lead sponsor | University of Rochester |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 84 |
| Start date | 3 November 2025 |
| Primary completion | 31 January 2027 |
| Estimated completion | 31 January 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- EEG measure of visual processing
Conditions studied
- Schizophrenia Disorders — all drugs for Schizophrenia Disorders →
- Bipolar Disorder — all drugs for Bipolar Disorder →
- Schizo Affective Disorder — all drugs for Schizo Affective Disorder →
Sponsor
University of Rochester
Who can join
Adults 18 to 65, any sex, with Schizophrenia Disorders or Bipolar Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to identify novel markers of psychosis using electroencephalography (EEG).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06911931
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Schizophrenia Disorders
Currently open trials in the same condition.
- NCT07010614 — Brain Stimulation to the Hippocampus in Schizophrenia · NA · recruiting
- NCT07098169 — Randomized Clinical Trial of iTEST: A Blended Intervention Targeting Introspective Accuracy · NA · recruiting
- NCT07082777 — Recovery in Telling Life Stories · NA · recruiting
- NCT06641726 — Creating a Global Research Database That Connects Genetic Information and Long-term Health Data to Improve Personalized · recruiting
- NCT06939088 — Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder · Phase 2 · recruiting
Other University of Rochester trials
Trials by the same sponsor.
- NCT07075965 — Calcium Channel Blocker in Myotonic Dystrophy Type 1 · Phase 1 · not yet recruiting
- NCT07423104 — A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloi · Phase 2 · not yet recruiting
- NCT05744869 — SBAT for Health Equity · NA · not yet recruiting
- NCT06052956 — Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses · Phase 2 · not yet recruiting
- NCT07032636 — Reducing Crises and Suicide Within the Idaho Army National Guard · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06911931 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Rochester
- Last refreshed: 12 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06911931.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing